11 research outputs found

    Efficacy and safety of combination of ulinastatin and meglumine cyclic adenosine monophosphate in the treatment of acute myocardial infarction, and its effect on serum levels of hs-CRP, cTnI and CK

    Get PDF
    Purpose: To determine the efficacy and safety of a combination of ulinastatin and meglumine cyclic adenosine monophosphate (cAMP) in the treatment of acute myocardial infarction (AMI), and its effect on serum levels of hypersensitive-c-reactive protein (hs-CRP), cardiac troponin I (cTnI), creatine kinase (CK).Methods: A total of 90 AMI patients admitted to The Second Affiliated Hospital of Qiqihar Medical College, Qiqihar City, Heilongjiang Province, China from January 2019 to January 2020 were selected and randomized (in a 1:1 ration) into control group and study group. Patients in the two groups received meglumine cAMP, while those in the study group were, in addition, treated with ulinastatin. The two groups were compared with regard to clinical efficacy, cardiac function indices, serum biochemical indices, incidence of drug-related side effects, duration and number of episodes of angina pectoris, and levels of neuroendocrine hormones.Results: The study group exhibited remarkably higher treatment effectiveness and cardiac function indices compared to the control group (p < 0.05). However, lower levels of serum biochemical indices, lower total incidence of drug toxicity, smaller number and shorter duration of angina pectoris, and lower levels of panel reactive antibodies (PRA) were observed in the study when compared to control group (p< 0.001).Conclusion: Treatment of AMI patients with the combination of ulinastatin and meglumine cAMP significantly reduces the clinical symptoms of the patients, with remarkable efficacy and high safety. Furthermore, it down-regulates serum levels of hs-CRP, cTnI and CK. Thus, the combination treatment seems superior to the conventional therapy

    Molecular dynamics simulations of oil recovery from dolomite slit nanopores enhanced by CO2 and N2 injection

    Get PDF
    Shale oil reservoirs are dominated by micro-and nanopores, which greatly impede the oil recovery rates. CO2 and N2 injection have proven to be highly effective approaches to enhance oil recovery from low-permeability shale reservoirs, and also represent great potential for CO2 sequestration. Therefore, a better understanding of the mechanism of shale oil recovery enhanced by CO2 and N2 is of great importance to achieve maximum shale oil productivity. In this paper, the adsorption behavior of shale oil and the mechanism of enhancing shale oil recovery by CO2 and N2 flooding in dolomite slit pores are investigated by performing nonequilibrium molecular dynamics simulations. Considering the shale oil adsorption behavior, mass density distribution is analyzed and the results indicate that a symmetric density distribution of the oil regarding the center in the slit pore along the x-axis can be obtained. The maximum density of the adsorbed layer nearest to the slit wall is 1.310 g/cm3 for C8H18 , which is about 2.0 times of that for bulk oil density in the middle area of slit pore. The interaction energy and radial distribution functions (between oil and CO2 , and between oil and N2 ) are calculated to display the displacement behavior of CO2 and N2 flooding. It is found that CO2 and N2 play different roles: CO2 has strong solubility, diffusivity and a higher interaction energy with dolomite wall, and the oil displacement efficiency of CO2 reaches 100% after 1 ns of flooding; however, during N2 flooding, the oil displacement efficiency is 87.3% after 4 ns of flooding due to the lower interaction energy between N2 and dolomite and that between N2 and oil.Cited as: Guo, H., Wang, Z., Wang, B., Zhang, Y., Meng, H., Sui H. Molecular dynamics simulations of oil recovery from dolomite slit nanopores enhanced by CO2 and N2 injection. Advances in Geo-Energy Research, 2022, 6(4): 306-313. https://doi.org/10.46690/ager.2022.04.0

    Orexins in the paraventricular nucleus of the thalamus mediate anxiety-like responses in rats

    No full text
    Anatomical studies have shown that the paraventricular nucleus of the thalamus (PVT) innervates areas of the forebrain involved in the expression and regulation of emotional behaviors including fear and anxiety. In addition, the PVT is densely innervated by fibers containing orexin-A (OXA) and orexin-B (OXB), peptides that are well-known for their arousal effects on behavior

    Orexins in the midline thalamus are involved in the expression of conditioned place aversion to morphine withdrawal

    No full text
    Previous studies have implicated the bed nucleus of the stria terminalis, central nucleus of the amygdala and the shell of the nucleus accumbens (collectively called the extended amygdala) as playing an important role in mediating the aversive emotion associated with opioid withdrawal. The paraventricular nucleus of the thalamus (PVT) provides a very dense input to the extended amygdala, and the PVT is densely innervated by orexin neurons, which appear to be involved in producing some of the physical and emotional effects associated with morphine withdrawal. In the present study, we confirm that the PVT is densely innervated by orexin fibers, whereas the regions of the extended amygdala associated with the effects of morphine withdrawal are poorly innervated. Microinjections of the orexin-1 receptor (OX1R) antagonist SB334867 or the orexin-2 receptor (OX2R) antagonist TCSOX229 at doses of 5.0 or 15.0 mu g into the PVT region did not affect the acquisition of the conditioned place aversion (CPA) nor the physical effects produced by naloxone-precipitated morphine withdrawal. In contrast, microinjections of TCSOX229 (15.0 mu g) in the PVT region significantly attenuated the expression of naloxone-induced CPA while microinjections of SB334867 at the same dose had no effect. The results from these experiments indicate a role for OX2R in the PVT on the expression of CPA associated with morphine withdrawal. Orexins may mediate the aversive effects of morphine withdrawal by engaging the extended amygdala indirectly through the action of orexins on the PVT. (C) 2010 Elsevier Inc. All rights reserved

    Changes in emotional behavior produced by orexin microinjections in the paraventricular nucleus of the thalamus

    No full text
    The paraventricular nucleus of the midline thalamus (PVT) innervates areas of the extended amygdala known to play a key role in the expression of emotional behaviors. In this study, microinjections of orexins (hypocretins), which have excitatory actions on neurons in the PVT, in the midline thalamus were used to investigate if the PVT modulates the expression of emotional behavior in the open field. First, the approach-avoidance tendency (number and duration of visit to the center area) associated with novelty was examined in orexin treated rats before and after placing a novel object in the center of the open field. Second, the expression of ethological behaviors (rearing, locomotion, freezing, and grooming) in the open field was used to determine the effects of orexins on emotionality. Microinjections of orexin-A (OXA) or orexin-B (OXB) in the PVT decreased exploration of the center area and the novel object indicating that the center area and the object had more aversive properties in orexin treated rats. Both OXA and OXB microinjections in the PVT increased the expression of freezing and grooming behaviors which are indicative of a negative emotional state. The results indicate that microinjections of orexins in the PVT made the test situation more aversive and produced avoidance behaviors. This suggests that orexins may act at the PVT to modulate behaviors associated with a negative emotional state. (C) 2010 Elsevier Inc. All rights reserved

    Orexins in the midline thalamus are involved in the expression of conditioned place aversion to morphine withdrawal

    No full text
    Previous studies have implicated the bed nucleus of the stria terminalis, central nucleus of the amygdala and the shell of the nucleus accumbens (collectively called the extended amygdala) as playing an important role in mediating the aversive emotion associated with opioid withdrawal. The paraventricular nucleus of the thalamus (PVT) provides a very dense input to the extended amygdala, and the PVT is densely innervated by orexin neurons, which appear to be involved in producing some of the physical and emotional effects associated with morphine withdrawal. In the present study, we confirm that the PVT is densely innervated by orexin fibers, whereas the regions of the extended amygdala associated with the effects of morphine withdrawal are poorly innervated. Microinjections of the orexin-1 receptor (OX1R) antagonist SB334867 or the orexin-2 receptor (OX2R) antagonist TCSOX229 at doses of 5.0 or 15.0 mu g into the PVT region did not affect the acquisition of the conditioned place aversion (CPA) nor the physical effects produced by naloxone-precipitated morphine withdrawal. In contrast, microinjections of TCSOX229 (15.0 mu g) in the PVT region significantly attenuated the expression of naloxone-induced CPA while microinjections of SB334867 at the same dose had no effect. The results from these experiments indicate a role for OX2R in the PVT on the expression of CPA associated with morphine withdrawal. Orexins may mediate the aversive effects of morphine withdrawal by engaging the extended amygdala indirectly through the action of orexins on the PVT. (C) 2010 Elsevier Inc. All rights reserved
    corecore